Allergan, Duke Get Generic Lash-Growth Treatments Blocked

Law360, New York (January 30, 2013, 4:39 PM ET) -- A North Carolina federal judge has blocked the release of generic versions of Allergan Inc. and Duke University’s Latisse eyelash growth stimulant, ruling three generics makers had infringed two Allergan and Duke patents.

According to U.S. District Judge Catherine C. Eagles’ Jan. 24 order, Apotex Inc., Sandoz Inc. and Hi-Tech Pharmacal Co. Inc.’s planned generic bimatoprost topical solutions indirectly infringe on two patents for topical solutions meant to stimulate mammalian hair growth — U.S. Patent Numbers 7,351,404 and 7,388,029, both issued in 2008 — and may...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

ALLERGAN, INC. et al v. APOTEX INC., et al


Case Number

1:10-cv-00681

Court

North Carolina Middle

Nature of Suit

Patent

Judge

CATHERINE C. EAGLES

Date Filed

September 8, 2010


Case Title

ALLERGAN, INC. et al v. SANDOZ, INC.


Case Number

1:11-cv-00298

Court

North Carolina Middle

Nature of Suit

Patent

Judge

CATHERINE C. EAGLES

Date Filed

April 15, 2011


Case Title

ALLERGAN, INC. et al v. HI-TECH PHARMACAL CO., INC.


Case Number

1:11-cv-00650

Court

North Carolina Middle

Nature of Suit

Patent

Judge

CATHERINE C. EAGLES

Date Filed

August 17, 2011

Law Firms

Companies

Patents